- April 27, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Synonyms :
Class :
systemic Lupus Erythematosus (SLE)
Indicated for the above condition in people who are already receiving a therapy
Intravenous
10 mg/kg intravenously every 2 weeks multiplied by 3 doses
Maintenance dose- 10 mg/kg intravenously every month
Subcutaneous
200 mg subcutaneously every week
If changing from intravenous to subcutaneous dose, administer the 1st subcutaneous dose 7-28 days later and the last intravenous dose
Indicated for the above condition in people who are already receiving a therapy
Intravenous
10 mg/kg intravenously every 2 weeks multiplied by 3 doses
Maintenance dose- 10 mg/kg intravenously every month
Subcutaneous
400 mg dose initially (divided into 2 injections) subcutaneously every week multiplied by 4 doses
Maintenance dose- 200 mg subcutaneously every week
belimumab's immunosuppressive properties reduce the efficacy of the live rotavirus oral vaccine, leading to diminished effects
belimumab's immunosuppressive properties reduce the efficacy of the live rotavirus oral vaccine, leading to diminished effects
belimumab's immunosuppressive properties reduce the efficacy of the live rotavirus oral vaccine, leading to diminished effects
belimumab's immunosuppressive properties reduce the efficacy of the live rotavirus oral vaccine, leading to diminished effects
belimumab's immunosuppressive properties reduce the efficacy of the live rotavirus oral vaccine, leading to diminished effects
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
it may reduce the therapeutic effect of covid-19 vaccines
may increase the risk of toxic effects when combined
may increase the risk or severity of adverse effects when combined
may decrease the therapeutic effect of COVID-19 vaccine
may enhance the risk of adverse effect when combined with belimumab
may increase the immunosuppressive effect of anti-psoriatic agents
may enhance the immunosuppressive effects of DMARDs
in combination with ofatumumab, belimumab increases the risk of adverse events.
it may increase the immunosuppressive effect of biologic disease-modifying antirheumatic agents
may increase the immunosuppressive effect
may increase the immunosuppressive effect
may have an increased immunosuppressive effect when combined with disease-modifying antirheumatic drugs
may have an increased immunosuppressive effect when combined with disease-modifying antirheumatic drugs
it may enhance the adverse effects when combined with aducanumab
it may enhance the risk of side effects when combined with mitomycin
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
may increase the risk or severity of infection when combined
It may enhance the adverse effects when combined with sotrovimab